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Aims Pre-operative renal dysfunction is a known risk factor for mortality and morbidity after heart
surgery. Despite limited accuracy, serum creatinine is widely used to estimate glomerular ﬁltration
rate (GFR). Cystatin C is more accurate for assessing GFR. The aim of the present study was to assess
associations between GFR estimated from serum cystatin C levels before heart surgery and hospital mor-
tality, hospital morbidity, and 1 year mortality.
Methods and results In a prospective single-centre observational study, clinical risk factors for mor-
bidity and mortality were recorded and serum creatinine and cystatin C levels were measured in
patients admitted for heart surgery. Hospital mortality and morbidity and 1 year mortality were
recorded. Over an 8 month period, 499 patients were screened, among whom 376 (74.5%) were
included in the study. Hospital mortality was 5.6% (21 patients) and 1 year mortality was 10.2%. Hos-
pital morbidity, deﬁned by a length of stay above the 75th percentile, was 22.1% (83 patients). In the
multivariable analysis, GFR estimated from serum cystatin C, but not GFR estimated from serum crea-
tinine, was an independent risk factor for hospital morbidity/mortality (odds ratio per 10 mL/min of
GFR decrease, 1.20 (1.07–1.34), P ¼ 0.001) and for 1 year mortality (hazards ratio per 10 mL/min of
GFR decrease, 1.26 (1.09–1.46), P ¼ 0.002).
Conclusion Pre-operativeGFRestimation from serumcystatin Cmay provide a better risk assessment than









The identiﬁcation of pre-operative risk factors for adverse out-
comes after heart surgery is important to determine which
resources and interventions will ensure an optimal outcome.
Another beneﬁt is risk adjustment in studies of quality of care.
Renal dysfunction increases the risk of peri-operative
morbidity and mortality in patients undergoing heart
surgery.1–8 The rate of chronic renal impairment is increas-
ing in the general population, and mild renal impairment
often escapes recognition.9 In numerous studies including
patients with cardiovascular disease or diabetes, glomerular
ﬁltration rate (GFR) was an independent risk factor for
overall mortality and new cardiovascular events.9 In clinical
practice, GFR is estimated from the serum creatinine level.
However, serum creatinine is of limited value for the early
detection of renal impairment, because creatinine is not
only ﬁltered by the glomeruli, but also secreted by the
tubules.10 Moreover, serum creatinine may not adequately
assess acute changes in GFR.11 Serum creatinine is inﬂu-
enced not only by renal function, but also by lean body
mass (i.e. muscle mass), sex, age, and ethnicity.12
Serum cystatin C is a newly identiﬁed marker of renal
function. Cystatin C is a low-molecular-weight protein
(13 359 Da) that is produced by all nucleated cells at a con-
stant rate, released into the bloodstream, freely ﬁltered by
the renal glomeruli, and catabolized in the proximal
tubules.13 Serum cystatin C concentration is independent
of age, sex, and muscle mass. Several studies have shown
that serum cystatin C is a better indicator of GFR and a
more reliable marker of mild renal dysfunction, compared
with serum creatinine.14–16 In an observational study,
Shlipak et al.17 found that serum cystatin C was an indepen-
dent risk factor for heart failure in elderly adults and a
better risk marker than serum creatinine.
In the present study, we hypothesized that pre-operative
GFR estimated from serum cystatin C would be a better pre-
dictor of post-operative mortality and morbidity than GFR




Over the period from March 2003 to January 2004, we conducted
a prospective observational study in a single university hospital.
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The study complied with the Declaration of Helsinki and was
approved by the institutional Ethics Committee. Informed consent
was obtained from all patients or from their guardians prior to
inclusion. Consecutive patients admitted for heart surgery were
included prospectively in the study.
Clinical assessments and follow-up
At baseline, we collected demographic characteristics, established
risk factors for heart surgery complications,18 and details on the
surgical procedure. With this information, we calculated the Euro-
SCORE19 for all patients. EuroSCORE stands for European System
for Cardiac Operative Risk Evaluation. This scoring system involves
17 variables distributed in three groups of risk factors: patient-
related factors, cardiac-related factors, and operation-related
factors. In the score, weights attributed to each variable were
obtained from the logistic regression beta coefﬁcients. At the end
of the hospital stay, we recorded new cardiac events, length of
ICU stay, length of hospital stay, and vital status. Finally, 1 year
after surgery, we contacted each patient’s general practitioner to
obtain information on vital status and hospital admissions. Our
primary endpoint was 1 year mortality. Secondary endpoints were
hospital mortality and hospital morbidity deﬁned as a length of hos-
pital stay greater than the 75th percentile, determined in the study
population. The choice of this length of stay threshold was made
arbitrarily but was justiﬁed by the fact that it maximized the prob-
ability that these patients truly presented comorbidity and that
they were those who inﬂated signiﬁcantly care cost.
Laboratory methods
In each patient, a 5 mL blood sample was drawn pre-operatively for
determination of serum creatinine using the kinetic compensated
Jaffe´ assay (CREA kit, Roche Diagnostics, Basel, Switzerland) and
of serum cystatin C using a particle-enhanced nephelometric immu-
noassay (N latex Cystatin C kit, Dade Behring, Marburg, Germany).
Serum creatinine levels were communicated to the physicians in
charge of the patients, but serum Cystatin C levels were not.
Creatinine based estimates of GFR were calculated using the
simpliﬁed version of the Modiﬁcation of the Diet in Renal Disease
(MDRD) formula:20 GFR (mL/min/1.73 m2) ¼ 186.3  serum creati-
nine concentration (mg/dL)21.154  age20.203  1.212 (if black) 
0.742 (if female).
Cystatin C based estimates of GFR were calculated using the
following formula:21 GFR (mL/min/1.73 m2) ¼ 84.69  Plasma
Cystatin C (mg/L)21.68  0.948 (if female). A GFR equal or above
90 mL/min/1.73 m2 was considered as normal.22
Statistical analysis
Continuous variables are reported as the median and interquartile
range. In addition to the studied markers of the renal function,
the following established risk factors were assessed in the univariate
analysis: age, female gender, chronic pulmonary disease, extra-
cardiac arteriopathy, previous cardiac surgery, active endocarditis,
critical pre-operative state, unstable angina, left ventricular
dysfunction, recent myocardial infarction, pulmonary hypertension,
emergent, surgery procedure other than isolated coronary surgery
and the EuroSCORE. To assess the relationship between cardiac
risk factors and renal function markers, we divided our study popu-
lation into quartiles of pre-operative GFR estimated from serum
cystatin C concentrations. We compared the characteristics of
patients across these quartiles using the likelihood ratio x2 test
and Kruskal–Wallis test as appropriate.
We performed univariate logistic regression and Cox proportional
hazard models to assess associations linking established risk factors
for cardiac surgery complications and renal function markers to hos-
pital mortality, hospital morbidity, and 1 year mortality. We then
used multivariable analysis (logistic regression and Cox proportional
hazard models) in order to assess associations between GFR
estimated from cystatin C or from creatinine with the outcome
when other risk factors are controlled. In this multivariable analysis,
we decided to use only the EuroSCORE as a control risk factor. Doing
so, we intended to avoid overﬁtting or underﬁtting, which would
have resulted if all the risk factors were included in the model
because of the small amount of outcome events (1 year survival
and hospital outcome). The choice of EuroSCORE as a risk adjust-
ment variable was reasonable since it is a well-validated tool for
risk assessment after heart surgery but also because it takes into
account all the risk factors mentioned earlier. We build two
models, one including the EuroSCORE and the GFR estimated from
cystatin C, the other including the EurosCORE and the GFR esti-
mated from creatinine. We assessed the ﬁt of these two models
by using the Akaike’s information criterion (AIC).
Finally, in order to select the variables having the strongest
association with the measured outcomes, we performed a backward
stepwise logistic regression and a backward stepwise Cox pro-
portional hazard regression including the following variables: Euro-
SCORE, GFR estimated with cystatin C, and GFR estimated with
creatinine. Variables with a signiﬁcant partial regression coefﬁcient
of P , 0.10 were added to the model, and those with P, 0.10 in the
stepwise procedure were retained.
Collinearity was checked with a matrix of correlations, using the
Spearman rank correlation coefﬁcient between independent vari-
ables. We chose an r  0.4 as the criterion for collinearity. A signiﬁ-
cant correlation (r ¼ 0.73, P, 0.001) was found between GFR
estimated from cystatin C and GFR estimated from creatinine.
Tests for linearity were performed for all continuous variables
(age, LVEF, EuroSCORE, creatinine, cystatin C, and the estimated
GFR). These variables were tested in two ways. First, a quadratic
term (x2) was included in addition to the linear term (x) in the logis-
tic and Cox regression models. A signiﬁcant coefﬁcient for x2 indi-
cates a lack of linearity. Secondly, continuous variables were
considered as categorical variables by dividing them into quartiles.
Then we ﬁtted univariate logistic regression model for the predic-
tion of hospital mortality and morbidity and a univariate Cox
model for 1 year survival analysis and plotted the average value
of each quartile vs. the coefﬁcient of the quartile. The plot was
then examined with respect to the shape of the resulting curve.
We found the relationship not linear only for serum creatinine.
The assumption of proportional hazards was checked by observing
a constant vertical difference between plots of log-integrated
hazard against t for the different quartiles of each variable. This
graphical assessment was further conﬁrmed using the Kolmogorov-
type supremum tests for proportional hazards assumption. We
found that proportional hazard assumption was respected for all
the variables.
Statistical tests were performed using SAS software (version 9.1.3
Service Pack 4, SAS Institute Inc., Cary, NC, USA). P-values lower
than 0.05 were considered statistically signiﬁcant.
Results
Baseline characteristics
Over the 8 month period, 499 patients admitted to our
heart surgery department were screened for study eligi-
bility. Among them, 376 (75.4%) patients gave their
informed consent before surgery and were included in
the study. Of the 123 patients who were not included in
the study, the reasons for non-inclusion in the protocol
were: 53/499 (11%) patients’ refusals; 32/499 (6%) unavail-
ability of a physician to obtain the informed consent;
26/499 (5%) patients in whom the study blood samples
were not drown pre-operatively; and 12/499 (2%) patients
who were too sick to give consent. Patients’ median age
was 71 years (range 20–86) and 254 (67.6%) patients
were men. The following surgical procedures were
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Table 1 Baseline characteristics of the study patients (n ¼ 376) by estimated GFR quartilesa
Patient characteristics All patients GFR estimated from serum cystatin C concentration P-value
Quartile 1 , 48 mL/
min/1.73 m2 (n ¼ 93)
Quartile 2 48–65 mL/
min/1.73 m2 (n ¼ 90)
Quartile 3 66–81 mL/
min/1.73 m2 (n ¼ 98)
Quartile 4  82 mL/
min/1.73 m2 (n ¼ 95)
Age, years 71 (63–76) 75 (70–78) 74 (69–78) 68 (60–72) 64 (57–71) ,0.001
Female, n (%) 122 (32.4) 39 (40.6) 35 (38.9) 21 (21.6) 27 (29.0) 0.015
Body mass index, kg/m2 26.1 (23.5–28.7) 26.3 (22.7–28.3) 25.7 (23.7–28.7) 26.4 (23.5–29.3) 25.4 (23.5–28.7) 0.765
EuroSCORE 5 (3–8) 6 (7–9) 6 (4.8–8.0) 5 (3.0–7.0) 3 (2.0–5.0) ,0.001
Pre-operative LVEF, % 63 (50–74) 58 (46–70) 62 (47–73) 69 (54.3–76.3) 65 (56.0–75.5) 0.003
COPD, n (%) 106 (28.2) 37 (38.5) 20 (22.2) 27 (27.8) 22 (23.7) 0.060
Diabetes, n (%) 81 (21.5) 29 (30.2) 20 (22.2) 15 (15.5) 17 (18.3) 0.077
Hypertension, n (%) 267 (71) 76 (79.2) 63 (70.0) 69 (71.1) 59 (63.4) 0.120
Pulmonary hypertension, n (%) 83 (22.1) 24 (25.0) 27 (30.0) 22 (22.7) 10 (10.8) 0.009
NYHA class IVb 31 (8.4) 16 (16.8) 4 (4.5) 6 (6.4) 5 (5.4) 0.013
Recent myocardial infarction, n (%) 51 (13.6) 14 (14.6) 11 (12.2) 16 (16.5) 10 (10.8) 0.667
Previous heart surgery, n (%) 24 (6.4) 12 (12.5) 2 (2.2) 5 (5.2) 5 (5.4) 0.035
Extracardiac arteriopathy, n (%) 94 (25) 35 (36.5) 20 (22.2) 26 (26.8) 13 (14.0) 0.004
Emergency surgery, n (%) 19 (5.1) 7 (7.3) 5 (5.6) 5 (5.2) 2 (2.2) 0.392
Complex surgeryc, n (%) 134 (35.6) 45 (46.9) 35 (38.9) 29 (29.9) 25 (26.9) 0.017
IABPd, n (%) 14 (3.7) 9 (9.4) 2 (2.0) 3 (3.4) 0 (0) 0.004
Serum cystatin C, mg/L 66 (49–81) 1.69 (1.53–1.99) 1.27 (1.21–1.33) 1.08 (1.06–1.1) 0.95 (0.83–0.98) ,0.001
Serum creatinine, mg/L 10.3 (8.7–12.1) 13.0 (11.1–16.4) 10.4 (9.0–12.0) 10.1 (8.7–11.2) 8.7 (7.7–9.9) ,0.001
Estimated GFR, cystatin C (mL/min) 66 (49–81) 35 (26–41) 55 (51–61) 73 (70–77) 91 (85–110) ,0.001
Estimated GFR, creatinine (mL/min) 71 (58–84) 50 (39–61) 66 (57–77) 77 (68–88) 87 (79–100) ,0.001
ICU stay, days 3 (2.3–5.0) 3 (2.0–4.0) 2 (2.0–4.0) 2 (2.0–3.0) ,0.001
Hospital stay, days 12 (10–16.8) 11 (10.0–14.3) 11 (10.0–14.0) 10 (10–12.0) 0.001
Death in the ICU, n (%) 9 (9.4) 1 (1.1) 2 (2.1) 0 (0) 0.001
Death in hospital, n (%) 21 (5.6) 13 (13.5) 4 (4.4) 3 (3.1) 1 (1.1) 0.002
1 year re-admission, n (%) 42 (11.3) 16 (34.8) 13 (15.3) 10 (10.8) 7 (7.7) 0.098
1 year mortality, n (%) 38 (10.1) 19 (19.8) 11 (12.2) 6 (6.2) 2 (2.2) ,0.001
IABP was used in case of failure to wean patient from cardiopulmonary bypass. LVEF, left ventricular ejection fraction; COPD, chronic obstructive pulmonary disease; GFR, glomerular ﬁltration rate; ICU, intensive
care unit.
aData are presented as median and interquartile range for continuous variables and count plus percentage for categorical variables.
bNYHA, New York Heart Association classiﬁcation system for heart dysfunction.
cMajor cardiac surgery other than or in addition to coronary artery bypass grafting.






performed: coronary artery bypass graft (CABG) 235/376
(62.5%); valve surgery 81/376 (21.5%); combined CABG
and valve surgery 38/376 (10.1%); ascending aorta surgery
15/376 (4%); atrial septal defect closure 5/376 (1.3%);
and left atrial myxoma surgery 2/376 (0.5%). Median
follow-up was 368 days; four patients (1.1%) were lost to
follow-up. Of the 376 patients, 21 (5.6%) died during the
hospital stay, 83 (22.1%) had a prolonged hospital stay
(longer than 75th percentile), and 38 (10.2%) died within
the ﬁrst year. The median and interquartile range of
serum creatinine were 10.3 (8.7–12.1) mg/L; and the
median and interquartile range of serum cystatin C were
1.16 (1.0–1.41) mg/L. Serum creatinine was above the
upper limit of normal (10.2 mg/L in women and 12.1 mg/L
in men) in 113 (30.1%) patients and serum cystatin C was
above the upper limit of normal (0.95 mg/L) in 322
(85.6%) patients. When serum creatinine was used, 302/
376 (80%) patients had an estimated GFR below normal,
whereas 323/376 (86%) patients had abnormal GFR when
serum cystatin C was used to estimate GFR. In 282
patients, GFR was below 90 mL/min/1.73 m2 whether it
was estimated with creatinine or with cystatin C (Table 1).
Cardiovascular risk factors and outcomes
associated with cystatin C
Patients in the lower quartile of GFR based on cystatin C
were older, more likely to be female, and more likely to
have risk factors for post-operative morbidity and mortality
as shown by higher EuroSCORE values.19 These patients were
also more likely to experience a prolonged ICU stay, a pro-
longed hospital stay, and death within the ﬁrst year after
surgery (Table 1).
Factors associated with 1 year mortality
Full follow-up data were obtained for all patients. In the
univariate analysis, in addition to estimated GFR, eight vari-
ables were signiﬁcantly associated with 1 year mortality:
age; EuroSCORE; COPD; recent myocardial infarction; extra-
cardiac arteriopathy; critical pre-operative state; unstable
angina; and emergency surgery. According to the AIC, the
multivariable model including EuroSCORE and GFR esti-
mated from Cystatin C (AIC ¼ 414.973) ﬁtted better than
the model including EuroSCORE and GFR estimated from
creatinine (AIC ¼ 417.204). Moreover, Euroscore and GFR
estimated from cystatin C were the two variables selected
by the backward stepwise logistic regression. When other
risk factors were adjusted, GFR estimated from cystatin C
was found to be a better marker for 1 year mortality than
GFR estimated from creatinine [odds ratio per 10 mL/min
of GFR decrease, 1.20 (1.07–1.34), P ¼ 0.001] (Table 2).
Factors associated with hospital morbidity or
mortality
In the univariate analysis, hospital mortality and morbidity
were signiﬁcantly associated with GFR, as well as with
seven of the 15 assessed risk factors (age, EuroSCORE,
COPD, diabetes mellitus, recent myocardial infarction, pre-
vious cardiac surgery, extracardiac arteriopathy, emergency
surgery, and complex surgery). Table 3 lists the other risk
factors. The multivariable model including EuroSCORE and
GFR estimated from cystatin C (AIC ¼ 368.591) ﬁtted
better than the model including the EuroSCORE and the
GFR estimated from creatinine (AIC ¼ 371.992). The Cox
regression model with backward stepwise variable selection
kept EuroSCORE and GFR estimated from cystatin C in the
Table 2 Univariate and multivariable Cox regression analysis for 1-year mortality rate
Patient characteristics Univariate analysis Multivariable analysis
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age, years 1.06 (1.02–1.10) 0.005
Female 0.85 (0.42–1.72) 0.653
EuroSCORE 1.23 ( 1.14–1.33) ,0.001 1.19 (1.09–1.29) ,0.001
COPD 2.18 (1.15–4.14) 0.017
Extracardiac arteriopathy 2.02 (1.05–3.87) 0.034
Previous heart surgery 1.39 (0.43–4.53) 0.581
Active endocarditis 1.02 (0.14–7.42) 0.986
Critical pre-operative state 4.98 (2.416–10.261) ,0.001
Unstable angina 2.51 (1.26–4.97) 0.008
Pre-operative LVEF, % 0.99 (0.97–1.01) 0.175
Recent myocardial infarction 2.78 (1.38–5.60) 0.004
Pulmonary hypertension 1.32 (0.64–2.72) 0.449
NYHA class IVa 1.37 (0.484–3.85) 0.557
Emergency surgery 4.82 (2.12–10.96) ,0.001
Complex surgeryb 0.87 (0.44–1.73) 0.697
Diabetes 1.54 (0.77–3.11) 0.225
Creatinine (mg/dL) 1.44 (1.11–1.86) 0.006
Cystatin C (mg/L) 1.67 (1.27–2.18) ,0.001
GFR estimated from cystatin C, mL/min/1.73 m2 0.97 (0.96–0.98) ,0.001 0.97 (0.96–0.99) 0.002
GFR estimated from creatinine, mL/min/1.73 m2 0.97 (0.95–0.98) ,0.001
LVEF, left ventricular ejection fraction; COPD, chronic obstructive pulmonary disease; 95% CI, 95% conﬁdence interval.
aNYHA, New York Heart Association classiﬁcation system for heart dysfunction.
bComplex surgery: major cardiac surgery other than or in addition to coronary artery bypass grafting.
Cystatin C blood level as a risk factor for death 1851
model [hazards ratio per 10 mL/min of GFR decrease, 1.26
(1.09–1.46), P ¼ 0.002].
After adjustment for other risk factors, GFR estimated
from cystatin C appeared to be a better marker for hospital
morbidity or mortality.
Discussion
In this prospective cohort study in 376 patients, we found
that pre-operative GFR estimated from serum cystatin C
was strongly associated with 1 year mortality and with hos-
pital mortality and morbidity. GFR estimated from serum
cystatin C was better than GFR estimated using MDRD
equation based on serum creatinine for predicting adverse
outcomes. Several reasons may explain our ﬁndings, as
serum cystatin C is more sensitive than serum creatinine
for detecting renal dysfunction. Serum creatinine tends to
overestimate GFR in patients with renal dysfunction. The
relationship between serum creatinine and GFR is not
linear, and serum creatinine starts to rise only when GFR
falls below 50% of normal.23 Therefore, serum creatinine
often misses mild-to-moderate renal function impairment.
Several mechanisms may contribute to worsen outcomes
after heart surgery in patients with renal dysfunction.
Renal dysfunction is associated with other risk factors such
as older age, left ventricle dysfunction, and extracardiac
arteriopathy (included in EuroSCORE). Renal dysfunction is
also associated with a wide range of metabolic derange-
ments, including hyperhomocysteinaemia,24 elevated asym-
metrical dimethylarginine,25 elevated lipoprotein (a),26
chronic inﬂammation, and increased oxidative stress.27
These derangements, which have been identiﬁed even in
patients with moderate renal dysfunction, are associated
with adverse outcomes in patients with kidney disease28–31
and may have mediated the higher risk seen in patients
with cystatin C elevation in our study.
GFR estimated from serum cystatin C adds information to
the EuroSCORE in terms of hospital mortality and morbidity.
This may be ascribable to the use of serum creatinine in the
EuroSCORE to estimate renal function. GFR estimated from
serum cystatin C was the only variable in our study that
added information to the EuroSCORE regarding 1 year mor-
tality. Although the EuroSCORE is not designed to predict
long-term outcomes, our ﬁndings constitute further evi-
dence that serum creatinine is not an optimal marker of
renal function and risk associated with heart surgery.
Serum creatinine assay is less expensive (0.4 US Dollars)
than cystatin C assay (5 US Dollars). Whether the greater
accuracy of cystatin C in estimating renal function is associ-
ated with clinical beneﬁts needs to be determined. Our
results suggest that the increased cost related to a
single pre-operative cystatin C measurement may be
acceptable in the setting of patient evaluation before
heart surgery. Shlipak et al.17 also found that cystatin C
was a better marker for the risk of death and cardiovascular
events than serum creatinine in elderly individuals. In
patients with acute coronary syndrome, cystatin C performs
better than creatinine in discriminating between survivors
and non-survivors.32 Thus, cystatin C assay may have a
favourable cost/beneﬁt ratio.
Our study has some limitations. Informed consent could not
be obtained for 123 patients (including 12 who were too sick
to give consent) of 499 admitted patients. Our study was
performed in a single centre, and its results may not apply
to other centres. A large multicentre study is needed to
further evaluate associations linking pre-operative cystatin C
Table 3 Univariate and multivariable logistic regression analysis to identify factors associated with hospital morbidity and mortality
Patient characteristics Univariate analysis Multivariable analysis
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Age, years 1.03 (1.01–1.06) 0.013
Female 0.77 (0.46–1.29) 0.316
EuroSCORE 1.23 (1.15–1.33) ,0.001 1.18 (1.10–1.28) ,0.001
COPD 1.69 (1.03–2.78) 0.040
Extracardiac arteriopathy 2.45 (1.48–4.07) 0.001
Previous heart surgery 4.02 (1.73–9.32) 0.001
Active endocarditis 3.16 (0.89–11.17) 0.074
Critical pre-operative state 5.94 (2.69–13.108) ,0.001
Unstable angina 1.52 (0.829–2.77) 0.177
Pre-operative LVEF, % 0.99 (0.98–1.01) 0.447
Recent myocardial infarction 1.82 (0.97–3.41) 0.063
Pulmonary hypertension 1.13 (0.65–1.97) 0.672
NYHA class IVa 1.81 (0.83–3.94) 0.135
Emergency surgery 4.61 (1.80–11.85) 0.001
Complex surgeryb 1.14 (0.70–1.85) 0.599
Diabetes 1.87 (1.10–3.19) 0.022
Creatinine (mg/dL) 2.84 (1.48–5.48) 0.002
Cystatin C (mg/L) 3.07 ( 1.74–5.41) ,0.001
GFR estimated from cystatin C, mL/min/1.73 m2 0.97 (0.96–0.98) ,0.001 0.98 (0.97–0.99) 0.001
GFR estimated from creatinine, mL/min/1.73 m2 0.97 (0.96–0.99) ,0.001
LVEF, left ventricular ejection fraction; COPD, chronic obstructive pulmonary disease; 95% CI, 95% conﬁdence interval.
aNYHA, New York Heart Association classiﬁcation system for heart dysfunction.
bComplex surgery: major cardiac surgery other than or in addition to coronary artery bypass grafting.
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to mortality after cardiac surgery. Another limitation is
that we did not study the cause of death in our patients
and therefore did not obtain data on the mechanisms
linking renal function impairment and outcomes.
Conclusion
Although the present study has to be considered as
preliminary, cystatin C appears to be a promising marker
for impaired renal function that provides more information
than the established estimates of GFR, thereby improving
the identiﬁcation of high-risk patients before heart surgery.
Conﬂict of interest: none declared.
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